Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis
Dates
study started
completion around
Principal Investigator
by Peter Belafsky, MD, PhD (ucdavis)Maggie Kuhn, MD (ucdavis)

Description

Summary

The primary objective of this study is to evaluate the safety of Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) during the 12 months following treatment of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous cell cancer of the oropharynx.

Official Title

Muscle Cell Mediated Therapy for Tongue Dysphagia: An Investigation of Cook MyoSite Autologous Muscle Derived Cells

Details

Keywords

Oropharyngeal Dysphagia, Deglutition Disorders, Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)

Eligibility

Location

  • UC Davis Medical Center, Department of Otolaryngology, Head and Neck Surgery
    Sacramento California 95817 United States

Lead Scientists at University of California Health

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Peter Belafsky, MD
ID
NCT02838316
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 18 people participating
Last Updated